SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by the Board of PTC Therapeutics, Inc.

Levi & Korsinsky announces it has commenced an investigation of PTC Therapeutics, Inc. (NASDAQ: PTCT) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On February 23, 2016, PTC announced receipt of a Refuse to File letter from the United States Food and Drug Administration (“the FDA”) regarding PTC’s New Drug Application for the drug Translarna. The FDA states in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review. On this news, PTC stock has fallen more than 40% on intraday trading on February 23, 2016. To obtain additional information, go to:

http://zlk.9nl.com/ptc-therapeutics-ptct

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160223006560/en/